The aim of this study was to evaluate the somatotroph axis in a large series of patients with prolactinoma to verify the prevalence of silent acromegaly in this population.
A hundred and forty-four patients were enrolled in a multicenter study: 90 were already on cabergoline (CAB) and enrolled in a cross-sectional arm (group A) with random PRL, GH and IGF-I determination on treatment (≥ 3 months), whereas 54 untreated patients were enrolled at diagnosis in a prospective arm (group B) with PRL, GH and IGF-I measurement before and after 6 and 12 months of treatment. In the presence of high IGF-I, CAB was withdrawn for 3 months and GH, IGF-I, PRL and GH during an oral Glucose Tolerance Test (OGTT) were obtained.
High IGF-I levels (ULN 1.01–1.56) were observed in 9 patients (6.25%, 5F). After CAB withdrawal, IGF-I levels normalized in 5/9 patients, GH was < 0.4 ng/ml after OGTT in 7/9 cases or at random GH determination in one case. After CAB re-introduction, IGF-I levels re-increased in a single case. Overall, a single young female patient harboring a macroadenoma in group A was diagnosed with silent acromegaly and underwent successful transsphenoidal removal of a GH/PRL-secreting adenoma.
The prevalence of silent acromegaly in prolactinomas (0.7%) is lower than previously reported and OGTT is helpful to recognize silent acromegaly. We suggest that the somatotroph axis should be evaluated at diagnosis in all cases and not systematically during follow-up.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Mulchahey JJ, Jaffe RB (1988) Detection of a potential progenitor cell in the human fetal pituitary that secretes both growth hormone and prolactin. J Clin Endocrinol Metab 66(1):24–32
Lloyd RV, Anagnostou D, Cano M, Barkan AL, Chandler WF (1988) Analysis of mammosomatotropic cells in normal and neoplastic human pituitary tissues by the reverse hemolytic plaque assay and immunocytochemistry. J Clin Endocrinol Metab 66(6):1103–1310
Bassetti M, Spada A, Arosio M, Vallar L, Brina M, Giannattasio G (1986) Morphological studies on mixed growth hormone (GH)- and prolactin (PRL)-secreting human pituitary adenomas coexistence of GH and PRL in the same secretory granule. J Clin Endocrinol Metab 62(6):1093–1100
Wang M, Mou C, Jiang M, Han L, Fan S, Huan C, Qu X, Han T, Qu Y, Xu G (2012) The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol 166(5):797–802. https://doi.org/10.1530/EJE-11-1119
Rosário PW, Purisch S (2010) Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists. Arq Bras Endocrinol Metabol 54(6):546–549
Bácsy E, Fazekas I, Slowik F, Pásztor E, Czirják S (1997) Transformation of a human mixed GH-PRL adenoma cell population in response to long-term bromocriptine treatment. Folia Histochem Cytobiol 35(2):69–74
Page MD, Bridges LR, Barth JH, McNichol AM, Belchetz PE (1996) Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma. J Clin Endocrinol Metab 81(12):4484–4487
Andersen M, Hagen C, Frystyk J, Schroeder HD, Hagen C (2003) Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 149(1):17–22
Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23(5):575–596. https://doi.org/10.1016/j.beem.2009.05.003
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265–273
Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, Wass JAH, Endocrine Society (2014) Acromegaly: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700
Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML, Endocrine Society (2011) Pituitary incidentaloma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:894–904
Peacey SR, Shalet SM (2001) Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly. Ann Clin Biochem 38(Pt 4):297–303
Manuylova E, Calvi LM, Hastings C, Vates GE, Johnson MD, Cave WT, Shafiq I (2016) Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Rep, pii: 16–0069.
Akirov A, Greenman Y, Glaser B, Schigol I, Mansiterski Y, Eizenberg Y, Shraga-Slutzky I, Shimon I (2018) IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Pituitary 21(4):406–413. https://doi.org/10.1007/s11102-018-0891-5
Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Piketty ML, Arnoux A, Young J, Souberbielle JC, Chanson P (2017) Classification of patients with GH disorders may vary according to the IGF-I assay. J Clin Endocrinol Metab 102(8):2844–2852
Lopes MB (2010) Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 29(4):E2. https://doi.org/10.3171/2010.7
Müller EE, Locatelli V, Cocchi D (1999) Neuroendocrine control of growth hormone secretion. Physiol Rev 79(2):511–607
Tannenbaum GS, Ling N (1984) The Interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 115(5):1952–1957
Arihara Z, Sakurai K, Yamashita R, Niitsuma S, Ueno T, Yamamura N, Yamada S, Inoshita N, Takahashi K (2014) Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly. Tohoku J Exp Med 234(2):129–135
Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale WW, Thorner MO (1987) Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. J Clin Endocrinol Metab 64(6):1136–1141
Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, Weiss MH (1981) Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47(4):761–771
Osamura RY, Grossman A, Korbonits M, Kovacs K, Lopes MBS, Matsuno A, Trouillas J (2017) Pituitary adenoma. In WHO Classification of tumours of endocrine organs; Chapter 1: Tumors of the pituitary gland; WHO: Lyon, France, pp. 14–18.
Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C (2020) How to classify the pituitary neuroendocrine tumors (Pit-NET)s in 2020. Cancers (Basel), 12(2).
Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A (2010) Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 95(1):13–17
Klibanski A, Zervas NT, Kovacs K, Ridgway EC (1987) Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J Neurosurg 66(6):806–811
Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G (2017) Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 176(2):195–201
This research received grant from Ipsen Biopharmaceuticals (Protocol n. 359/2013).
Conflict of interest
There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
All patients filled informed consent statement for this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bona, C., Prencipe, N., Jaffrain-Rea, M.L. et al. The prevalence of silent acromegaly in prolactinomas is very low. J Endocrinol Invest (2020). https://doi.org/10.1007/s40618-020-01338-x
- Silent acromegaly
- Dopamine agonists